Welcome to our dedicated page for Thermo Fisher Scientific news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fisher Scientific stock.
Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific (NYSE: TMO) reported a strong second quarter for 2020, with revenue up 10% to $6.92 billion and a 28% increase in adjusted EPS to $3.89. The growth was fueled by approximately $1.3 billion in COVID-related revenue and strategic initiatives, including enhanced PCR testing capabilities and collaborations for antibody testing. While GAAP operating income decreased from the prior year, adjusted metrics showed significant improvement, reflecting strong demand and operational efficiency.
Thermo Fisher Scientific (NYSE: TMO) announced major expansions in its global pharma services network to support over 200 projects related to COVID-19 treatments and vaccines. The U.S. government's BARDA is providing funding to boost manufacturing capacity for sterile injectables. The company is also expediting the delivery of existing therapies, producing a year’s worth of a common anti-inflammatory treatment in just months. Their site-to-patient program ensures continuous access to critical medicines for clinical trial participants.
Thermo Fisher Scientific (NYSE: TMO) announced a quarterly cash dividend of $0.22 per common share, payable on October 15, 2020, to shareholders of record as of September 15, 2020. The company reported annual revenue exceeding $25 billion and aims to enable healthier, cleaner, and safer environments through innovative technologies and services. With a global workforce of over 75,000, Thermo Fisher delivers industry-leading solutions across various sectors, including life sciences and diagnostics.
Thermo Fisher Scientific (TMO) estimates approximately 10% revenue growth for Q2 2020, driven by strong global sales of PCR-based tests and COVID-19 response products, generating over $1.4 billion in revenue. The company will announce its Q2 financial results on July 22, 2020, followed by a conference call at 8:30 a.m. ET. With annual revenue exceeding $25 billion, Thermo Fisher is committed to advancing health and safety globally.